Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153062 · ClinicalTrials.gov registry record · Phase 4
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 20,332
- Enrollment target
NCT00153062: Completed Phase 4 study, sponsored by Boehringer Ingelheim.
NCT00153062 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 20,332 participants, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3840% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00153062, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20,332 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
Interventions
- DRUG Aggrenox
- DRUG Clopidogrel placebo
- DRUG Micardis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,332 participants |
| Start Date | 2003-08 |
| Phase | Phase 4 |
What the finished NCT00153062 record still lists
NCT00153062 is an interventional study that assigns participants to a tested intervention. Its 20,332 participants enrollment target places it among the larger protocols in the corpus, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3840% higher).
The record links to 0 conditions, and to 3 interventions - of which Aggrenox is the first listed.
NCT00153062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00153062 about?
NCT00153062 is a clinical study titled "PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes". The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of back...
What is the current status of trial NCT00153062?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20,332 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00153062?
The interventions under investigation include: Aggrenox (DRUG), Clopidogrel placebo (DRUG), Micardis (DRUG).
Who is sponsoring clinical trial NCT00153062?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00153062's enrollment target sits among peer trials
20,332 5th of 2000 higher than 1,996 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia